Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-8575130-B2
Publication Date
2013-11-05
Expiration Date
Abstract
The present invention is related to a hyaluronic acid formulation including a mixture of hyaluronic acids having different weight-average molecular weight and different rheological, tissue scaffold, insulation and degradation properties in aqueous solution. The resulting formulation demonstrated an optimal balance between adhesion, tissue scaffold, insulation and treating time on the treatment and prevention of IBD (inflammatory bowel disease) such as ulcerative colitis and Crohn's disease. Thus, the formulation of the present invention exhibits a quick and lasting effect on the treatment and prevention of duodenal or peptic ulcer and bleeding which is very good thing indeed.
Core Innovation
The invention relates to a mixture of hyaluronic acid for treating inflammatory bowel disease (IBD). The mixture consists essentially of hyaluronic acids with a lower molecule weight (Mw of LMWHA) and a higher molecule weight (Mw of HMWHA), and the average Mw of LMWHA is defined as 1 million Da while the average Mw of HMWHA is defined as 2 million Da.
The hyaluronic acid mixture further specifies a mixing ratio of LMWHA and HMWHA in a range from 20:80 to 80:20. The concentration of the mixture of LMWHA and HMWHA in a solution is defined as 0.5 mg/mL to 50 mg/mL, and in defined embodiments the mixture concentration is narrowed to 0.5 mg/mL to 5 mg/mL and the mixing ratio is narrowed to 1:1.
The invention also includes using the hyaluronic acid mixture for treating IBD, and for irritable bowel syndrome (IBS). The concept of the mixture is tied to a combination of hyaluronic acid fractions having distinct average molecular weights and the resulting rheology, adhesion, insulation, and degradation characteristics.
Claims Coverage
The partial claim set includes two independent claims. Both claims center on a hyaluronic acid mixture defined by two molecular-weight fractions, with a defined mixing-ratio range and a defined concentration-in-solution range; the second independent claim additionally limits use to treating IBD or irritable bowel syndrome (IBS).
Mixture of low and high molecular weight hyaluronic acids for IBD treatment
A mixture of hyaluronic acid consisting essentially of hyaluronic acids with a lower molecule weight (Mw of LMWHA) and a higher molecule weight (Mw of HMWHA), wherein the average Mw of LMWHA is 1 million Da and the average Mw of HMWHA is 2 million Da; and treating inflammatory bowel disease (IBD).
Defined LMWHA:HMWHA mixing ratio range
A mixing ratio of said LMWHA and said HMWHA in a range from 20:80 to 80:20.
Defined concentration of the LMWHA/HMWHA mixture in solution
Wherein the concentration of the mixture of said LMWHA and said HMWHA in a solution is 0.5 mg/mL to 50 mg/mL.
Use of the mixture for IBD or IBS
Wherein said mixture of hyaluronic acid is used for treating inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS).
Across the independent claims, the inventive concept is captured by defining a hyaluronic acid mixture as consisting essentially of LMWHA and HMWHA with specified average molecular weights, constraining the LMWHA:HMWHA mixing ratio (20:80 to 80:20), constraining the concentration in solution (0.5 mg/mL to 50 mg/mL), and limiting the use to treating IBD and, in one independent claim, IBS as well.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Treating inflammatory bowel disease (IBD).
Treating irritable bowel syndrome (IBS).
Treatment and prevention of ulcerative colitis, Crohn’s disease, and related wound healing in the stomach and intestine, including duodenal or peptic ulcer and bleeding.
Interested in licensing this patent?